

Amendments to the Claims:

1. (Currently Amended) ~~The use of an extract from plant material of the species Trichilia sp., wherein it is used for the combat, reversion and/or prevention of ventricular fibrillation~~ A method for the combat, reversion and/or prevention of ventricular fibrillation, comprising the administration of an extract from plant material of the species Trichilia sp. to a patient in need thereof.

2. (Currently Amended) ~~The use according to The method of~~ claim 1, wherein the plant material is *Trichilia catigua* A. Juss.

3. (Currently Amended) ~~The use according to The method of~~ claim 1 or 2, wherein the plant material is *Trichilia catigua* A. Juss and ~~it is~~ said extract is administered in association with an extract of *Paullinia cupana* (Sapindaceae), *Croton moritibensis* (Euphorbiaceae) and *Zingiber officinale* (Zingiberaceae).

4. (Currently Amended) ~~The use according to The method of~~ claim 1, 2 or 3, wherein the extract is in the form of a product or pharmaceutical composition particularly having the following composition:

Liquid formulation:		
Component	% (m/v)	
	Generic	Preferred
Extract of <i>Trichilia</i> sp. (specially <i>Trichilia catigua</i> A. Juss)	0.50 to 10.0	0.50 to 5.00
Extract of <i>Paullinia cupana</i>	0.10 to 7.50	0.1 to 5.00
Extract of <i>Croton moritibensis</i>	0.01 to 5.50	0.01 to 5.0
Extract of <i>Zingiber officinale</i>	0.10 to 2.00	0.1 to 0.40
Suitable excipient	79.50 to 99.29	84.60 to 99.24

Solid formulation:		
Component	% (m/m)	
	Generic	Preferred
Extract of <i>Trichilia</i> sp. (specially <i>Trichilia catigua</i> A. Juss)	5 to 100	30 to 50
Extract of <i>Paullinia cupana</i>	2 to 30	10 to 21
Extract of <i>Croton moritibensis</i>	0.2 to 15.0	5 to 12
Extract of <i>Zingiber officinale</i>	0.5 to 3.0	0.5 to 1.5
Suitable excipient	2 to 92.30	15.5 to 54.5

5. (Currently Amended) ~~The use according to The method of~~ claim 4, wherein the product or pharmaceutical composition in its dry and excipient-free form has the following composition:

Formulation		
Component	% (m/m)	
	Generic	Preferred
Extract of <i>Trichilia</i> sp. (specially <i>Trichilia catigua</i> A. Juss)	17 to 100	22 to 34
Extract of <i>Paullinia cupana</i>	24 to 57	32 to 48
Extract of <i>Croton moritibensis</i>	17 to 40	22 to 34
Extract of <i>Zingiber officinale</i>	2 to 5	2.5 to 4.0

6. (Currently Amended) ~~The use according to The method of claim 1, any of claims 1 to 3, wherein said use is for comprising~~ the combat/reversion of spontaneous and electrical stimulus-induced ventricular fibrillation.

7. (Currently Amended) ~~The use according to The method of~~ claim 6, wherein said

~~use is for comprising~~ the reversion of spontaneous and electrical stimulus-induced ventricular fibrillation.

8. (Currently Amended) ~~The use according to The method of claim 1, any of claims 1 to 7, wherein said use is for comprising~~ the prevention of ventricular fibrillation.

9. (Currently Amended) ~~The use according to The method of claim 1, any of claims 1 to 7, wherein said use is for comprising~~ the treatment of ventricular fibrillation of any etiology.

10. (Currently Amended) ~~The use according to The method of claim 1, any of claims 1 to 7, wherein said use is for comprising~~ post-fibrillation treatment in order to maintain regular cardiac rhythm.

11. (Currently Amended) A pharmaceutical composition, wherein said composition comprises plant material of the species *Trichilia* sp., alone or ~~not~~ in association with an extract of one or more of the following plants: *Paullinia cupana* (Sapindaceae), *Croton moritibensis* (Euphorbiaceae) and *Zingiber officinale* (Zingiberaceae) for combating/reverting spontaneous and electrical stimulus-induced ventricular fibrillation.

12. (Currently Amended) The pharmaceutical composition of claim 11  
~~Pharmaceutical composition according to claim 11~~, wherein said pharmaceutical composition has the composition as defined in claim 4 ~~any of claims 4 or 5~~.

13. (Currently Amended) The pharmaceutical composition of claim 11  
~~Pharmaceutical composition according to claim 11~~, wherein the plant material is *Trichilia catigua* A. Juss., alone or in said association, for the reversion of spontaneous and electrical stimulus-induced ventricular fibrillation.

14. (Currently Amended) The pharmaceutical composition of claim 11

~~pharmaceutical composition according to any of claims 11 to 13, wherein said pharmaceutical composition~~ it is used for the treatment and/or prevention of ~~ventricular fibrillation any of the pathologies as defined in claims 6 to 10.~~

15. (Original) A method for reverting/combating ventricular fibrillation, wherein said method comprises the administration of a product or extract comprising plant material of the species Trichilia sp. to a patient in need thereof.

16. (Currently Amended) ~~The method of claim 15~~ A method for reverting ventricular fibrillation according to claim 16, wherein the plant material is Trichilia catigua A. Juss.

17. (Currently Amended) ~~The method of claim 15~~ The method for reverting/combating ventricular fibrillation according to claim 15, wherein said product has a composition as defined in ~~claim 4~~ any of claims 4 or 5.

18. (Currently Amended) ~~The method of claim 15~~ The method of treatment and/or prevention according to any of claims 15 to 17, wherein said method is for the treatment and/or prevention of ~~ventricular fibrillation any of the pathologies as defined in claims 6 to 10.~~

19. (Currently Amended) A method for preparing a pharmaceutical composition for reverting, combating and/or preventing ventricular fibrillation A use of a product comprising plant material of the species Trichilia sp., alone or in association with an extract of one or more of the following plants: Paullinia cupana (Sapindaceae), Croton moritibensis (Euphorbiaceae) and Zingiber officinale (Zingiberaceae), ~~wherein said plant material~~ it is used for preparing a pharmaceutical composition for reverting, combating and/or preventing ventricular fibrillation.

20. (Currently Amended) ~~The method of~~ The use according to claim 19, wherein the plant material is Trichilia catigua A. Juss and ~~said plant material~~ it is used for the reversion of ventricular fibrillation.

21. (Currently Amended) The method of The use according to claim 19, wherein said product is in the form of a product or pharmaceutical composition has the composition as defined in claim 4 any of claims 4 or 5.

22. (Currently Amended) The method of The use according to claim 19 or 21, wherein the product is used for the reversion of ventricular fibrillation as described in ventricular fibrillation any of the pathologies as defined in claims 6 to 10.